Annals of The Japanese Respiratory Society:A case of lung adenocarcinoma that developed pembrolizumab-induced myasthenia gravis but in which the drug was able to be continuously administered

Abstract

Full Text of PDF (314k)
Article in Japanese

Case Report

A case of lung adenocarcinoma that developed pembrolizumab-induced myasthenia gravis but in which the drug was able to be continuously administered

Mutsumi Ozasa^a Toyomitsu Sawai^a Yosuke Harada^a Sumako Yoshioka^a Nobuko Matsuo^a Hiroshi Mukae^b

^aDepartment of Respiratory Medicine, Nagasaki Harbor Medical Center
^bSecond Department of Internal Medicine, Nagasaki University Hospital

ABSTRACT

A 59-year-old man had been treated with pembrolizumab for right lung adenocarcinoma. After six courses, he developed right ptosis with circadian variation, and edrophonium tests were positive; he was diagnosed with pembrolizumab-induced myasthenia gravis (MG). In this case, the symptoms of pembrolizumab-induced MG, but pembrolizumab administration was able to be continued for two years without any follow-up.

KEYWORDS

Pembrolizumab Immune checkpoint inhibitor (ICI) Myasthenia gravis (MG) Immune-related adverse event (irAE) Edrophonium

Received 23 Dec 2019 ／ Accepted 3 Aug 2020

AJRS, 9(6): 454-457, 2020

Search for	AJRS(after 2012) JJRS(before 2011) Both of which
Year	equal after before
Volume	equal after before	Number	equal after before
Title		Author
Abstract		Keywords

Content

Abstract

Case Report

ABSTRACT

KEYWORDS